転移性大腸癌（mCRC）の2L治療におけるNIS793とその他の新規治験薬とSOC抗癌剤の併用療法に関する研究

基本情報

NCT ID: NCT04952753
ステータス: 中止
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 204
治験依頼者名: Novartis

概要

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.

対象疾患

Metastatic Colorectal Cancer

介入

NIS793(DRUG)

Bevacizumab(DRUG)

Modified FOLFOX6(DRUG)

FOLFIRI(DRUG)

Tislelizumab(DRUG)

依頼者（Sponsor）

ノバルティスファーマ株式会社(INDUSTRY)